Shares of Eli Lilly have recently gained upward momentum after the Canadian Drug Agency (CDA) issued a positive reimbursement recommendation for its eczema treatment, Ebglyss (lebrikizumab), paving the way for coverage under national public drug plans across Canada.

Ebglyss received authorization from Health Canada in June 2024 for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents aged 12 and older. This conditional recommendation from the CDA-AMC represents a key federal-level advancement, following a positive opinion from Quebec's health technology assessment agency, INESSS, in August 2024. Concurrently, the pan-Canadian Pharmaceutical Alliance has reached a letter of intent with Lilly Canada for all jurisdictions, indicating the drug's potential for public reimbursement nationwide.

Mathilde Merlet, General Manager of Lilly Canada, stated that this move will provide patients across Canada with access to an advanced biologic proven to offer sustained long-term efficacy with a confirmed safety profile. Amanda Cresswell-Melville, Executive Director of Eczema Society of Canada, also noted that this positive recommendation is a significant step in expanding treatment options, offering healthcare providers greater flexibility and patients a better opportunity to manage their condition.

The authorization for Ebglyss is based on results from several pivotal clinical studies, including ADvocate 1, ADvocate 2, and ADhere. Data show the drug can achieve 90% skin clearance and significant itch relief as early as week 4. Its long-term extension study, ADjoin, further indicates that skin clearance and itch relief can be maintained for up to two years, with the latest data supporting sustained efficacy for up to four years. For investors, the progress of Ebgyss underscores that Eli Lilly's growth extends beyond the weight-loss drug sector, with its diversified pipeline continuing to deliver value.